Aug. 25 at 1:59 PM
$XXII Why XXII Stands Out
🔷 FDA Authorization – The only commercially available low-nicotine combustible cigarettes authorized by the FDA in the U.S.
🔷 Proprietary Non-GMO Technology – Patented plants that deliver full flavor with 95% less nicotine.
🔷 Expanding Reach – Strategic launches (Like California, New York and New Jersey) and growing retailer interest.
🔷 Strong Momentum – New marketing leadership, rising consumer adoption, and a robust patent portfolio.
🔷 Positive Public Health Angle – Products backed by science showing potential to reduce dependence while preserving the familiar smoking ritual.
22nd Century isn’t just another tobacco company. They’re building a new generation of tobacco—one that prioritizes choice, innovation, and lower use. With high-margin growth potential, an expanding product lineup, and a clear mission to put power back in consumers’ hands, XXII is positioning itself at the center of a major industry shift.
Don't miss out...
Research (NASDAQ: XXII) now before they SKYROCKET.
